Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
Status:
RECRUITING
Trial end date:
2028-09-15
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm, open-label, dose-escalation, early-phase 1 study to evaluate the safety, tolerability and preliminary efficacy of ZZSW-01 injection in patients with relapsed/refractory B-cell malignancies.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology